Puma Biotechnology Inc Common Stock (PBYI)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Puma Biotechnology is a $522.4M market-cap biopharma selling NERLYNX for HER2-positive breast cancer. At the 2026-10-13 close of $10.12, FairStock calculations show P/E 19.84, P/B 3.73, FCF yield 7.9%, EV/EBITDA 10.86, and PEG 0.50. The business has produced real profit: in fiscal year 2025, the year ended 2025-12-31, revenue was $228.4M and net income $31.1M, or $0.61 diluted EPS; in fiscal year 2024, the year ended 2024-12-31, revenue was $230.5M and net income $30.3M; in fiscal year 2023, the year ended 2023-12-31, revenue was $235.6M and net income $21.6M. Profits improved while revenue was flat to slightly lower—cost discipline, not top-line momentum. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $56.5M, net income $8.2M, and diluted EPS $0.16. But fiscal Q1 2026, the quarter ended 2026-03-31, had revenue of $44.8M and a net loss of $3.8M, or $-0.07 EPS, showing lumpiness. The balance sheet looks conservative: the given debt-to-equity is 0.03, while FairStock shows ROE 21.97%, ROCE 9.81%, and TTM free cash flow of $41.2M. Piotroski is 7/9. Yet Altman Z is -2.49 and the Graham Number is $5.58, with a FairStock margin of safety of -81.36% at the close. The computed Lynch category is STALWART, with profit 2396.3% a year over three years and revenue 0.0%. The moat is narrow: one main commercial drug and 179 employees. I see a profitable but single-product, revenue-stagnant company; price looks full versus Graham but cheaper on cash flow and PEG.

In plain English: Puma Biotechnology sells NERLYNX, a medicine for a type of breast cancer. The company is profitable and carries little debt, but sales have been roughly flat and it relies on one main product. At $10.12, the stock looks expensive compared with its earnings and assets, but more reasonable compared with the cash it produces.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer